Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cochlear implants cases in Tennessee: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 23% on average (17 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 6 | 135 | 43% |
| 2020 | 3 | 131 | 46% |
| 2021 | 4 | 127 | 49% |
Cochlear implantation, children and adults. Professional codes (what the surgeon bills): CPT 69930.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Tennessee; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 40 | 3,324+0.1%/yr | +0.1%/yr | 4.80.9× | 84% | 4,300 in 2030+4.4%/yr |
| Ear tubes & middle ear surgery |
Cochlear implants in every state, and its device makers · Every procedure market in Tennessee · Every state · Compare with Florida
| 2024 |
| 205 |
| 57% |
| 2025 est. | ≈ 190 | – |
| 2026 est. | ≈ 210 | – |
| 2022 | 5 | 129 | 52% |
| 2023 | 8 | 174 | 55% |
| 2024 | 7 | 205 | 57% |
| 2025 from claims | – | 192 155–226 | 57% |
| 2026 forecast | – | 209 164–263 | 58% |
| 2027 forecast | – | 228 169–301 | 58% |
| 2028 forecast | – | 248 176–343 | 58% |
| 2029 forecast | – | 270 184–388 | 59% |
| 2030 forecast | – | 294 193–437 | 59% |
In 2025, 72% hospital outpatient, 28% surgery center. The share outside the hospital has moved +28 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| +1.6%/yr |
| 0.1 |
| 13% |
| 330 in 2030+2.2%/yr |
| North Carolina | 5 | 192+9.9%/yr | +9.9%/yr | 0.2 | 21% | 300 in 2030+7.5%/yr |
| South Carolina | 6 | 142+4.7%/yr | +4.7%/yr | 0.2 | 17% | 310 in 2030+14%/yr |
| Georgia | 4 | 121+12%/yr | +12%/yr | 0.1 | 0% | 230 in 2030+11%/yr |
| Maryland | 4 | 116+2.8%/yr | +2.8%/yr | 0.1 | 0% | 100 in 2030−2.1%/yr |
| Virginia | 3 | 115+6.7%/yr | +6.7%/yr | 0.1 | 0% | 150 in 2030+4.4%/yr |
| 2 |
| 283−4.9%/yr |
| −4.9%/yr |
| 0.41.2× |
| 69% |
| 250 in 2030−2.3%/yr |
| Sleep apnea & airway implants | 4 | 136+52%/yr | +52%/yr | 0.20.8× | 0% | 200 in 2030+6.7%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Integra LifeSciences leads with 45% of company spending on these surgeons in 2025, −7 pts on 2024.
In 2025, 7 companies reported engagement with Tennessee’s surgeons worth $5,655 in consulting, speaking, meals and travel tied to these products, about $808 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 15 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.